NCT02723071View on ClinicalTrials.gov

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Ocrelizumab

Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.

Trial Locations (23)

1211

Geneva

3002

Melbourne

3010

Bern

4102

Woolloongabba

6000

Perth

6900

Lugano

10126

Torino

14186

Huddinge

20502

Malmo

22185

Lund

24127

Bergamo

35033

Rennes

44093

Nantes

59037

Lille

69495

Pierre-Bénite

90185

Umeå

94010

Créteil

T6G 1Z2

Edmonton

V5Z 4E6

Vancouver

B3H 2Y9

Halifax

K1H 1C4

Ottawa

M5G 2M9

Toronto

00161

Roma

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02723071 - A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL) | Biotech Hunter | Biotech Hunter